Huntington Hospital, a specialist in stroke care, has collaborated with Viz.ai to launch its first US FDA approved computer-aided triage system in the Los Angeles area, it was reported on Wednesday.
Huntington Hospital has installed this applied artificial intelligence-based technology to help facilitate early access to the most advanced stroke care. Viz.ai solutions is intended to enable Huntington Hospital to further improve the power of its stroke care team through rapid detection and notification of suspected LVO strokes and allow stroke specialists to securely communicate to synchronise care and determine the optimal patient treatment decision.
Arbi Ohanian, MD, medical director of Huntington Hospital's Stroke Program, Huntington Hospital, said, 'With stroke, time is brain. Viz.ai's applied artificial intelligence solutions have been developed by top stroke clinicians and technical experts in the world and we are excited to be able to bring these transformational technologies to Huntington Hospital and our community. It truly changes the way that we deliver stroke care which we believe will result in improved outcomes for our patients.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval